Aeovian Pharmaceuticals Raises $37 Million Series A Financing

Aeovian Pharmaceuticals, a company developing innovative therapies for the treatment of rare and age-related diseases, today announced the close of a $37 million Series A financing co-led by venBio Partners and Sofinnova Investments, alongside founding investors Apollo Health Ventures and Evotec SE. The proceeds from this financing will be used to advance its lead selective mTORC1 inhibitor, AE116, from the preclinical stage through clinical proof of concept for an undisclosed rare disease of the central nervous system (CNS).